29 filings · most recent first
JNJ 8-K Filings
Johnson Johnson Completes Acquisition Of Firefly Bio Inc And Updates Financial
Johnson Johnson Announces Proposed Resolution Of Ovarian Talc Litigation
Johnson Johnson Reports Strong Q2 2026 Results And Raises Outlook
Johnson Johnson Shareholders Approve Key Proposals At 2026 Annual Meeting
Johnson Johnson Reports Strong Q1 2026 Results And Increases Dividend
Johnson Johnson Announces Strong Q4 And Fullyear 2025 Results
Johnson Johnson Completes Public Offering Of New Notes
Johnson Johnson Completed Public Offerings Of Various Notes
Johnson Johnson Completes Public Offerings Of Multiple Notes
Johnson Johnson Reports Strong Q3 2025 Results And Announces Orthopaedics
Johnson Johnson Appoints John Morikis To Board Of Directors
Johnson Johnson Reports Q2 2025 Results And Raises Outlook
Johnson Johnson Appoints Daniel Pinto To Board Of Directors
Johnson Johnson Director Retirement And Annual Meeting Results
Johnson Johnson Reports Q1 2025 Financial Results With Strong Sales Growth And
Johnson Johnson Bankruptcy Plan Denied
Johnson Johnson Reports Q4 And Fullyear 2024 Financial Results And Provides
Johnson Johnson Reports Q4 2024 Financial Results And Pipeline Progress
Johnson Johnson Announces Q3 2024 Financial Results And Updates Guidance
Johnson Johnsons Subsidiary Files For Chapter 11 Bankruptcy To Resolve Talc
Johnson Johnson Announces Retirement Of Director D S Davis
Johnson Johnson Announces Retirement Of Chief Human Resources Officer
Johnson Johnson Reports Q2 2024 Financial Results And Updates Guidance
Johnson Johnson Completes Separation From Kenvue Via Debtforequity Exchange
Johnson Johnson Announces Plan Of Reorganization For Ovarian Cancer Claims
Johnson Johnson Adopts New Bylaws And Shareholder Approvals At 2024 Annual
Johnson Johnson Corrects Q1 2024 Sales Guidance Midpoint
Johnson Johnson Announces Strong Q1 2024 Performance And Dividend Increase
Johnson Johnson Reports Strong 2023 Financial Results And Key Regulatory